(NASDAQ: TRAW) Traws Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.32%.
Traws Pharma's earnings in 2026 is -$14,750,000.On average, 4 Wall Street analysts forecast TRAW's earnings for 2026 to be -$38,711,474, with the lowest TRAW earnings forecast at -$40,237,147, and the highest TRAW earnings forecast at -$36,588,866. On average, 4 Wall Street analysts forecast TRAW's earnings for 2027 to be -$37,475,180, with the lowest TRAW earnings forecast at -$52,857,654, and the highest TRAW earnings forecast at -$20,521,581.
In 2028, TRAW is forecast to generate -$10,663,041 in earnings, with the lowest earnings forecast at -$10,244,882 and the highest earnings forecast at -$10,976,660.